Why wasn't he made to stay... Either they realised that he would be an overpaid director doing practically nothing.. Alternatively he realised that he made a big mistake either internally or selling QP out before they could show what they were capable of.
I,d be interested in peoples views, but this being a bizaar share as no one seems to air any opinions on this either way..
INMO.. This will either be a stellar share or the next p...pck.. So DYOR
Looks like this was over priced when they stitched up Qp shareholders.
An I on my own thinking that the CEO together with his board only looked after themselves..
What a surprise.
I am little baffled as to what value he added.. A ten year old would have able to work out that closing a loss making devision to only focus on the profitable was the way forward.. He evidently could not add any value after doing the obvious.. So sold out when basically he had nothing to do and not being capable of taking the company forward.
the cash element is below what I paid so I can use the loss against other capital gains. Its a calculation I still need to do whether its now or in the future, so having the base cost is still necessary to me. Anyone know what that base cost is please?
I want to work out the base cost and CGT situation on the QP takeover. Im clear that receiving part cash for the takeover constitutes a disposal for CGT purposes, but how much do I apportion to the cash and how much to the new Clinigen shares? what percentage?
And secondly is the value attributed to the Clinigen shares received, the closing price of Clinigen shares on 1 Nov when the deal completed?
There may be good reasons for Glass selling all his shares but seems a little unusual and a bit unsettling. SP on the slide in last few days, not sure if this contributed.
Several board changes announced of late, but Mr. Glass not one of them.
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services group, announces that it was notified on 30 October 2017 that the following transaction took place on 30 October 2017.
Steve Glass, Chief Commercial Officer, sold 17,360 ordinary shares of 0.1 pence each in the Company at a price of 1131 pence per share.
Following this transaction, Mr Glass no longer holds any ordinary shares in the Company.
With the price increasing toward the £11 recently due to the purchasing of Quantum Pharma I have decided to sell my shares today after several years of holding.
I feel the company may now be overvalued for the time being, it has around £1 per shares worth of tangible assets, and £2 worth of equity within the company. Revenue only increased 7 % last year, although gross profit did increase 22%.
This is not to say that the company is in excellent shape financially, and the management are obviously keen to expand its 'empire' with the prospect of adding Quantum Pharma.
This is a good buy with obvious parallels to Clinigens own business, but Quantum Pharma did state a loss with write downs on deadwood business last year, and I still question the current business value with Quantum Pharma figures in the mix.
Quantum Pharma plc is a growing manufacturer, supplier and service provider within the pharmaceutical sector. It is a market leader (in terms of its size or its service offering) in each of the niche markets in which it operates. Its customers include pharmaceutical wholesalers and retail pharmacies, hospitals, pharmaceutical companies, care homes and home care operators. Quantum's core business is the manufacture, procurement and supply to major UK pharmacy chains, wholesalers and hospitals of Specials and Special Obtains. Specials are medicines which are not licensed for general manufacture, which are prescribed for a specific patient need and which are manufactured or procured under an MHRA licence. Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from a mainline pharmaceutical wholesaler. Quantum has a range of around 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK. Through acquisition and investment, Quantum has expanded into additional markets, including aseptic compounding and supplying home care and care home patients. The Group has gained access to overseas markets via U L Medicines Limited, significant product development and licensing expertise through Colonis Pharma Limited and has entered into a joint venture in the Republic of Ireland.
"Daniel Nickols, manager of the Old Mutual UK Smaller Companies fund, tells Marina Gerner which stocks he has been buying, selling and holding recently.Daniel Nickols has been the lead manager of FUND:A3I9:Old Mutual UK Smaller Companies since ..."
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.